CD274 and hepatocellular carcinoma: Currently, blocking the signaling of the programmed cell death receptor-1 (PD-1) and programmed cell death receptor ligand-1 (PD-L1) pathways with monoclonal antibodies is a new immunotherapeutic approach for treating advanced HCC cases.